Scientists report an advance toward “structure-based drug design,” with the potential to delay or treat Alzheimer’s disease, Parkinson’s disease, type II diabetes, ALS (also known as Lou Gehrig’s disease) and many other degenerative diseases.
Scientists report an advance toward “structure-based drug design,” with the potential to delay or treat Alzheimer’s disease, Parkinson’s disease, type II diabetes, ALS (also known as Lou Gehrig’s disease) and many other degenerative diseases.